ID: MRFR/HC/6927-HCR | February 2021 | Region: Global | 111 pages
Global Gene Therapy Market was valued USD 524 million in2018 and expected to register a CAGR of 40.7%.
The research and development, along with increased investment in product development is driving the global gene therapy market.
Acquisitions of small-scale companies by key players and a large number of ongoing clinical trials are driving the market.
Frequently Asked Questions (FAQ) :
The global gene therapy market had reached a valuation of USD 524 MN in 2018.
The global gene therapy market is projected to grow at approximately 40.7% CAGR during forecast period (2019-2025).
Rising technological advances and favorable government initiatives.
North America holds the largest share in the global gene therapy market, followed by Europe and the Asia Pacific, respectively.
Novartis AG (Switzerland), Amgen, Inc. (US), Spark Therapeutics, Inc. (US), uniQure N.V. (Netherlands), Gilead Sciences, Inc. (US), Orchard Therapeutics plc (UK), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), and CEVEC (Germany), are some of the major players operating in the gene therapy market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.